Table 1.

Describe the distribution of various clinicopathological variables with leptin immunostaining in breast cancer

		Leptin immunostaining
		Negative		Low		High
		Count	Row N %	Count	Row N %	Count	Row N %	P-Value
Type of tissue	Leptin in breast cancer	73	16.3%	274	61.0%	102	22.7%	0.0778
	Leptin in control group	2	7.4%	14	51.9%	11	40.7%
Age in Years	<40	16	23.2%	30	43.5%	23	33.3%	0.0233
	40–49	16	14.0%	67	58.8%	31	27.2%
	50–59	24	17.9%	89	66.4%	21	15.7%
	60–69	11	16.2%	46	67.6%	11	16.2%
	> = 70	6	11.8%	31	60.8%	14	27.5%
	NA	0	0.0%	11	84.6%	2	15.4%
Hormone receptor phenotype	ER- PR- HER2-	16	23.2%	36	52.2%	17	24.6%	0.0021
	ER- PR- HER2+	6	8.8%	40	58.8%	22	32.4%
	ER- PR+ HER2-	0	0.0%	2	28.6%	5	71.4%
	ER- PR+ HER2+	0	0.0%	7	77.8%	2	22.2%
	ER+ PR- HER2-	7	14.0%	33	66.0%	10	20.0%
	ER+ PR- HER2+	3	17.6%	11	64.7%	3	17.6%
	ER+ PR+ HER2-	34	23.6%	81	56.3%	29	20.1%
	ER+ PR+ HER2+	7	8.2%	64	75.3%	14	16.5%
ER	ER-	22	14.4%	85	55.6%	46	30.1%	0.0279
	ER+	51	17.2%	189	63.9%	56	18.9%
PR	PR-	32	15.7%	120	58.8%	52	25.5%	0.4410
	PR+	41	16.7%	154	62.9%	50	20.4%
HER	HER2-	57	21.1%	152	56.3%	61	22.6%	0.0021
	HER2+	16	8.9%	122	68.2%	41	22.9%
Lymph node involvement	NEGATIVE	33	17.8%	100	54.1%	52	28.1%	0.0300
	POSITIVE	40	15.2%	174	65.9%	50	18.9%
Size of tumor	<2	10	16.7%	34	56.7%	16	26.7%	0.5784
	>5	13	12.0%	68	63.0%	27	25.0%
	2–5	50	17.8%	172	61.2%	59	21.0%
Grade	I	13	17.8%	42	57.5%	18	24.7%	0.0500
	II	45	18.8%	151	63.2%	43	18.0%
	III	15	10.9%	81	59.1%	41	29.9%
Histotype	DCIS	4	23.5%	9	52.9%	4	23.5%	0.0001
	Ductal	65	15.9%	255	62.2%	90	22.0%
	Mucinous carcinoma	0	0.0%	1	11.1%	8	88.9%
	Lobular	4	30.8%	9	69.2%	0	0.0%
Stage	I	8	16.0%	27	54.0%	15	30.0%	0.0291
	II(a)	24	18.3%	69	52.7%	38	29.0%
	II(b)	22	15.8%	92	66.2%	25	18.0%
	III	4	6.1%	49	74.2%	13	19.7%
	IV	15	23.8%	37	58.7%	11	17.5%
Vascular Invasion	Negative	55	17.8%	184	59.5%	70	22.7%	0.4058
	Positive	18	12.9%	90	64.3%	32	22.9%
Recurrence	No	57	14.3%	253	63.4%	89	22.3%	0.0023
	Yes	16	32.0%	21	42.0%	13	26.0%